2seventy bio
TSVT

$4.79

5.25%

Market Cap: 246M

About: 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

Employees: 425

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 5 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

22% more capital invested

Capital invested by funds: $206M [Q4 2023] → $251M (+$45.2M) [Q1 2024]

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

2% more funds holding

Funds holding: 113 [Q4 2023] → 115 (+2) [Q1 2024]

4.02% less ownership

Funds ownership: 95.18% [Q4 2023] → 91.17% (-4.02%) [Q1 2024]

43% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 46

44% less call options, than puts

Call options by funds: $707K | Put options by funds: $1.26M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$5

4%

upside

Avg. target

$10.20

113%

upside

High target

$18

276%

upside

5 analyst ratings

3 positive

60%

2 neutral

40%

0 negative

0%

Wedbush David Nierengarten	4%upside $5	Neutral Reiterated	27 Jun 2024
Canaccord Genuity John Newman	130%upside $11	Buy Maintained	9 May 2024
Citigroup Samantha Semenkow	151%upside $12	Buy Maintained	8 Apr 2024
Wedbush David Nierengarten	4%upside $5	Neutral Reiterated	18 Mar 2024
Leerink Partners Daina Graybosch	276%upside $18	Outperform Upgraded	31 Jan 2024

See Analyst Rankings

Financial journalist opinion

2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition

2seventy bio, Inc. focuses on Abecma, an FDA-approved CAR T cell therapy for multiple myeloma. TSVT's strategic realignment includes selling non-core assets to Regeneron and Novo Nordisk. Abecma shows favorable clinical data but faces strong competition from Carvykti.

2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition

3 Hidden Stock Gems That Wall Street Is Overlooking

No matter your investing style, we all hope to find overlooked stock gems. These are where the biggest gains are made.

3 Hidden Stock Gems That Wall Street Is Overlooking

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease. The 2seventy bio team currently involved in the program will join No.

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

2seventy bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA in a virtual fireside chat on Tuesday, May 28, 2024 at 8:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL, on Monday, June 10, 2024 at 8:40 a.m. ET Live webcasts of the fireside chats will be available via.

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs Chip Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmann - Chief Medical Officer Conference Call Participants Rabib Chaudhury - Leerink Partners Matt Leskowitz - Goldman Sachs Kelsey Goodwin - Guggenheim Securities Morgan Gryga - Morgan Stanley John Newman - Canaccord Genuity Operator Good day and thank you for standing by. Welcome to the 2seventy bio First Quarter 2024 Earnings Conference Call.

2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

Zacks Investment Research

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.08 per share a year ago.

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024. “In the first quarter of 2024, we have successfully completed a strategic re-alignment to focus exclusively on Abecma, seeking to impact many more patients in earlier lines and return to commercial growth. In turn, we are focused on reaching financial sustainability and creating value for shareholders,” said Chip Baird, CEO, 2se.

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the c.

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

Zacks Investment Research

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

See News Rankings